BackHims & Hers Health Overview
Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Target Price

See Hims & Hers Health's analyst price targets ($32) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$27.99

Average Target Price

$32.0014.3% upside

11 analysts in the last 4 months

High: $42 | Low: $23

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-24Truist Financial$3214.3% upsideOpen
2026-08-20BarclaysGlen Santangelo$3525% upsideOpen
2026-08-11Deutsche BankGeorge Hill$267.1% downsideOpen
2026-08-11NeedhamRyan MacDonald$4250.1% upsideOpen
2026-08-11Morgan Stanley$280% upsideOpen
2026-07-09UBS$3732.2% upsideOpen
2026-07-01Canaccord Genuity$4042.9% upsideOpen
2026-06-17Barclays$3939.3% upsideOpen
2026-06-02Leerink PartnersMichael Cherny$2510.7% downsideOpen
2026-05-26UBS$2510.7% downsideOpen
2026-05-22UBS$2317.8% downsideOpen
2026-05-12Jefferies$24.512.5% downsideOpen
2026-05-12UBS$3525% upsideOpen
2026-05-12Canaccord Genuity$3214.3% upsideOpen
2026-05-05Deutsche BankGeorge Hill$2510.7% downsideOpen
2026-03-10Deutsche Bank$280% upsideOpen
2026-03-09NeedhamRyan MacDonald$307.2% upsideOpen
2026-03-09Oppenheimer$12.555.3% downsideOpen
2026-02-24Barclays$2510.7% downsideOpen
2026-02-24Morgan StanleyCraig Hettenbach$2125% downsideOpen
2026-02-24Evercore ISI$2414.3% downsideOpen
2026-02-24Truist FinancialJailendra Singh$1835.7% downsideOpen
2026-02-24Leerink Partners$17.537.5% downsideOpen
2026-02-10Deutsche BankGeorge Hill$3110.8% upsideOpen
2026-02-09Leerink PartnersMichael Cherny$2028.5% downsideOpen
2026-02-02BTIG$60114.4% upsideOpen
2026-01-08Wolfe Research$293.6% upsideOpen
2025-12-08Barclays$4871.5% upsideOpen
2025-12-04Leerink PartnersMichael Cherny$4146.5% upsideOpen
2025-11-12Morgan StanleyCraig Hettenbach$4042.9% upsideOpen
2025-11-04Seaport Global$59110.8% upsideOpen
2025-11-04Truist FinancialJailendra Singh$3732.2% upsideOpen
2025-11-04UBS$3214.3% upsideOpen
2025-11-04Leerink PartnersMichael Cherny$4664.3% upsideOpen
2025-06-24Truist FinancialJailendra Singh$4560.8% upsideOpen
2025-06-23UBS$307.2% upsideOpen
2025-06-04NeedhamRyan Macdonald$65132.2% upsideOpen
2025-02-19Canaccord GenuityMaria Ripps$68142.9% upsideOpen
2024-12-02Canaccord GenuityMaria Ripps$3835.8% upsideOpen
2024-11-05Piper SandlerKorinne Wolfmeyer$2125% downsideOpen
2024-11-05NeedhamRyan MacDonald$280% upsideOpen
2024-10-29Leerink PartnersMichael Cherny$267.1% downsideOpen
2024-10-21Bank of America SecuritiesMichael Cherny$2510.7% downsideOpen
2024-10-14Bank of America SecuritiesMichael Cherny$2317.8% downsideOpen
2024-10-14Truist FinancialJailendra Singh$2317.8% downsideOpen
2024-09-13Bank of America SecuritiesAllen Lutz$2028.5% downsideOpen
2024-08-27CitigroupDaniel Grosslight$2028.5% downsideOpen
2024-08-07JefferiesGlen Santangelo$1835.7% downsideOpen
2024-08-06Deutsche BankGeorge Hill$2317.8% downsideOpen
2024-05-22Canaccord GenuityMaria Ripps$2414.3% downsideOpen

Hims & Hers Health (HIMS) FAQ

Hims & Hers Health's target price stands at $32. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $32 for HIMS implies 14.3% upside versus today's price ($27.99). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Hims & Hers Health's target price evolved across reporting periods, while the comparison chart places HIMS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Consumer Staples, target price is commonly used to spot outliers. Hims & Hers Health's reading of $32 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.